On Friday, August 26th, Sephora brings its innovative BEAUTY TIP (Teach, Inspire, Play) WORKSHOP concept store to the Midwest with the opening of its new Michigan Avenue store. Chicago’s revolutionary new shopping experience will be the fourth Sephora BEAUTY TIP Workshop in the U.S., joining San Francisco’s Powell Street, Boston’s Prudential Center, and Toronto’s Yorkdale Shopping Centre locations which opened within the last year, and marks the global beauty retailer’s 400th free-standing SEPHORA store in North America.
Sephora Michigan Avenue’s BEAUTY TIP WORKSHOP, an all-new 10,040 square foot street-level store, is Sephora’s fourth largest and reflects the next-generation of the continuously evolving Sephora experience. The virtual paradise of endless beauty options includes an exciting footprint that’s both distinctive and intuitive, with over 13,000 products, and a pioneering store environment rooted in discovery and innovation. This includes a wide array of services and classes that will make a visit to the store a one-of-a-kind, individualized experience, every time.
To view the multimedia release go to:
http://www.multivu.com/players/English/7749653-sephora-chicago-400th-store-opening
Chiasma, Inc., a U.S. privately–held biopharma company developing octreotide capsules for the orphan condition acromegaly, today announced two new studies presented at the 97th Endocrine Society (ENDO) Annual Meeting in San Diego, Calif. The studies provide additional data from Chiasma’s Phase III trial and new findings on the patient burden of current injection therapies.
“We now have data to help clinicians determine whether octreotide capsules, if approved, are likely to help their patient with acromegaly maintain response,” said Shlomo Melmed, M.D., senior vice president and dean, Cedars–Sinai Medical Center, Los Angeles and global study principal investigator. “Furthermore, the Phase III results show the safety and efficacy of octreotide capsules can be reliably determined within 12 weeks of initiating therapy.”
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7436451-endo-chiasma-clinical-data/
The countdown to Super Bowl 50 has begun! As fans nationwide finalize their Super Bowl Sunday plans and snacks starting lineup, it’s hard to choose which delicious dishes make the final cut! Will it be helmet shaped cookies? Or football fields made from guacamole and sour cream? Once you have your half-time snacks lined up, it’s also important to not fumble when it comes to the perfect beverage.
This year, why not try a new spin on an old favorite with some Fizzology, an innovative approach that reimagines the way you can enjoy soda through non-alcoholic mixology. Fizzology combines unexpected flavors and ingredients that excite your taste buds – imagine sprinkles and shredded coconut topping your favorite Pepsi soda. It’s a great way to be creative and playful in how you experience and enjoy drinking a soda – especially when you’re watching Super Bowl 50!
Whether you are celebrating at home or in the stadium, you can elevate your Super Bowl 50 experience by bringing some fizzology to the party. At the NFL Experience in San Francisco visit F!ZZ, a playful celebration of bubbles with unexpected ingredient combinations -- including flavor shots, bursts, garnishes and foams -- creating a fun, adventurous way for consumers to deconstruct and reconstruct soda.
To view the multimedia release go to:
http://www.multivu.com/players/English/7743251-pepsi-fizz-drinks-super-bowl-50/
As part of an ongoing commitment to support life sciences innovators and the development of integrated, cross-sector solutions to prevent, intercept and cure diseases, Johnson & Johnson today named cell biologist Yoshinori Ohsumi, Ph.D., of the Tokyo Institute of Technology the winner of the 2016 Dr. Paul Janssen Award for Biomedical Research for his pioneering discoveries concerning the molecular basis of autophagy.
Dr. Ohsumi was honored today during an event at the 2016 BIO International Convention in San Francisco. A video of his acceptance comments can be viewed here.
“Dr. Ohsumi’s curiosity led him to become the first person in the world to determine the molecular mechanism and regulation of autophagy, shedding light on one of the most basic functions of all living cells,” said Paul Stoffels, M.D., Chief Scientific Officer, Johnson & Johnson. “Dr. Ohsumi’s discoveries hold promise for better understanding, preventing and treating many diseases. It is with great pleasure that we celebrate his contributions, which remind us of the innovative spirit Dr. Paul brought to the lab every day.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7856351-2016-dr-paul-janssen-award-ohsumi/
Pek çok hayvan (buna biz insanlar da dahiliz) problem çözme yetisine sahipler. Beyinlerini kullanmayı ve düşünmeyi gerektiren pek çok bilmecenin altından rahatlıkla kalkıyorlar. Ancak bugün hala ilkel inançlardan doğan bir söylem almış başını gidiyor: "Hayvanlar düşünemez, Allah aklı sadece insana bahşetmiştir."
Kendimizi üstün görme anlayışına sahip olduğumuz ne yazık ki bir gerçek. Bu durum akrabalarımızın ve diğer canlıların başarılarını hep gözardı etmemize ya da önyargıyla yaklaşmamıza sebep oluyor. Sadece primatlar değil pek çok türden canlı bugün düşünmelerini gerektiren zeka problemlerinin üstesinden ustalıkla geliyorlar.
Combining their expertise in clinical trials support and cellular therapies, BloodCenter of Wisconsin (BCW) and the San Diego Blood Bank (SDBB) have created a strategic partnership to accelerate advancements in research and patient care. Together, BloodCenter of Wisconsin and San Diego Blood Bank will offer Celluvative™ – a portfolio of products and clinical trial services that will include esoteric laboratory testing, blood products for research and manufacturing applications, cell processing, and access to a broad database of diverse donors who have expressed interest in clinical trials.
“Through the strength of our partnership, we are able to offer end-to-end services to academic organizations, research institutions and other industry partners who are working to develop novel cellular therapy approaches,” said Matthew Anderson, M.D., Ph.D., medical director, BloodCenter of Wisconsin Diagnostic Laboratories. “Among other offerings, our Celluvative portfolio enables access to an extremely diverse donor database – an invaluable resource to enable advances in the area of regenerative medicine and drug discovery.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7855451-bloodcenter-sdbb-celluvative/
On February 26, the Salt Institute unveiled a unique advertising campaign featuring a new character for its brand: Olde Salty.
This salt-of-the-earth character is the newest ideation from advertising agency Grey San Francisco. The campaign features a series of videos in which the post-nautical sage slides across icy roads, shares virgin tequila shots, and even feeds his pet clam a few dashes of the institute's favorite mineral. It’s a well-balanced blend of entertainment and the benefits of one the world’s most versatile and savory products—and it's nothing short of white gold.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7458351-olde-salty-conversation-salt/
America’s traffic congestion recession is over. Just as the U.S. economy has regained nearly all of the 9 million jobs lost during the downturn, a new report produced by INRIX and the Texas A&M Transportation Institute (TTI) shows that traffic congestion has returned to pre-recession levels.
According to the 2015 Urban Mobility Scorecard, travel delays due to traffic congestion caused drivers to waste more than 3 billion gallons of fuel and kept travelers stuck in their cars for nearly 7 billion extra hours – 42 hours per rush-hour commuter. The total nationwide price tag: $160 billion, or $960 per commuter.
Washington, D.C. tops the list of gridlock-plagued cities, with 82 hours of delay per commuter, followed by Los Angeles (80 hours), San Francisco (78 hours), New York (74 hours), and San Jose (67 hours).
To view the multimedia release go to:
http://www.multivu.com/players/English/7430751-inrix-2015-urban-mobility-scorecard/
Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today that its first doses of the Fluzone® (Influenza Vaccine) portfolio for the 2017-2018 influenza (“flu”) season have been released by the U.S. Food and Drug Administration (FDA). Sanofi Pasteur has begun distributing initial shipments, representing the first of nearly 70 million total doses of seasonal influenza vaccine manufactured by the company for this upcoming influenza season. Widespread shipment of Fluzone Quadrivalent, Fluzone High-Dose and Fluzone Intradermal Quadrivalent vaccine to health care provider offices, pharmacies and other immunizers will begin in early August to support fall immunization campaigns.
“As we enter the Swiftwater site’s 120th year, it reminds us of our innovation and growth as we came to understand the science of influenza and its impact on human health,” said David P. Greenberg, M.D., Associate Vice President and Regional Medical Head North America, Sanofi Pasteur. “Influenza can be especially severe for the most vulnerable populations, including the elderly, young children and those with compromised immune systems; however, it can also have a serious health impact on otherwise healthy individuals. Sanofi Pasteur is and always has been deeply committed to improving public health by continuously striving to develop new vaccines and on improving existing ones.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8081151-sanofi-pasteur-influenza-vaccine-first-shipment-2017/
Paulie Rhyme's latest video off his project, Less Than Zero Volume 2, presented by Terry Urban and MICK. Produced by Killah Kilam. Shot by No Harm No Fowl in San Francisco at Ocean Beach. More information on Paulie Rhyme at www.infinityfunk.com
